In an independent analysis of prescription drug treatments for hypertension, the Evanston, IL-based health data company Solucient found that 49% of patients who were started on an ACE inhibitor had no prior history of hypertension treatment during the previous 12 months. Moreover, three in four of those patients also had no history of heart failure or diabetes, two conditions that indicate ACE inhibitors as a first-line hypertension therapy.
In an independent analysis of prescription drug treatments for hypertension, the Evanston, IL-based health data company Solucient found that 49% of patients who were started on an ACE inhibitor had no prior history of hypertension treatment during the previous 12 months. Moreover, three in four of those patients also had no history of heart failure or diabetes, two conditions that indicate ACE inhibitors as a first-line hypertension therapy.
These findings suggest that many physicians may prescribe drugs in the ACE inhibitor class more readily for first-line high blood pressure treatment than is recommended in guidelines such as those published by the National Institutes of Health.
The often-controversial guidelines, from the NIH's "Sixth Annual Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure," indicate that beta-blockers or diuretics should be the first course of hypertension treatment for all patients except those with a history of diabetes or congestive heart failure.
The analysis of hypertension drug patterns was conducted through Solucient's new ScriptSwitch study, which tracks drug usage and patterns.
The ScriptSwitch study also found that about one in six patients who started an ACE inhibitor as the only therapy stopped it and was not administered any other treatment for at least 60 days. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.